000276063 001__ 276063
000276063 005__ 20240229154954.0
000276063 0247_ $$2doi$$a10.1016/j.molmed.2023.04.005
000276063 0247_ $$2pmid$$apmid:37179132
000276063 0247_ $$2ISSN$$a1471-4914
000276063 0247_ $$2ISSN$$a1471-499X
000276063 0247_ $$2altmetric$$aaltmetric:148237430
000276063 037__ $$aDKFZ-2023-00969
000276063 041__ $$aEnglish
000276063 082__ $$a610
000276063 1001_ $$0P:(DE-He78)8267c7c8b2e91db98a49f832eb5b99bb$$aJin, Fukang$$b0$$eFirst author$$udkfz
000276063 245__ $$aARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.
000276063 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2023
000276063 3367_ $$2DRIVER$$aarticle
000276063 3367_ $$2DataCite$$aOutput Types/Journal article
000276063 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1690460847_31843$$xReview Article
000276063 3367_ $$2BibTeX$$aARTICLE
000276063 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276063 3367_ $$00$$2EndNote$$aJournal Article
000276063 500__ $$a#EA:A430#LA:A430# / 2023 Aug;29(8):646-658
000276063 520__ $$aMutations in the AT-interacting domain-rich protein 1A (ARID1A) gene, a critical component of the switch/sucrose nonfermentable (SWI/SNF) complex, are frequently found in most human cancers. Approximately 5-10% of lung cancers carry ARID1A mutations. ARID1A loss in lung cancer correlates with clinicopathological features and poor prognosis. Co-mutation of ARID1A and epidermal growth factor receptor (EGFR) results in the limited efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) but increases the clinical benefit of immune checkpoint inhibitors (ICIs). ARID1A gene mutation plays a role in cell cycle regulation, metabolic reprogramming, and epithelial-mesenchymal transition. We present the first comprehensive review of the relationship between ARID1A gene mutations and lung cancer and discuss the potential of ARID1A as a new molecular target.
000276063 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000276063 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276063 650_7 $$2Other$$aARID1A
000276063 650_7 $$2Other$$aSWI/SNF complex
000276063 650_7 $$2Other$$acell cycle regulation
000276063 650_7 $$2Other$$aepithelial–mesenchymal transition
000276063 650_7 $$2Other$$alung cancer
000276063 650_7 $$2Other$$ametabolic reprogramming
000276063 7001_ $$aYang, Zhiguang$$b1
000276063 7001_ $$aShao, Jingbo$$b2
000276063 7001_ $$0P:(DE-He78)27fb0d2bd2832c8c977e636025736942$$aTao, Jianxin$$b3$$udkfz
000276063 7001_ $$aReißfelder, Christoph$$b4
000276063 7001_ $$0P:(DE-He78)1eee9e84c0f8c90a97fe40b6e8252a23$$aLoges, Sonja$$b5$$udkfz
000276063 7001_ $$0P:(DE-He78)0116f5652cc0dbf455e3aa3914740230$$aZhu, Lei$$b6$$udkfz
000276063 7001_ $$0P:(DE-He78)a9d57fe3333789705a9ceb9ca904e83e$$aSchölch, Sebastian$$b7$$eLast author$$udkfz
000276063 773__ $$0PERI:(DE-600)2155736-6$$a10.1016/j.molmed.2023.04.005$$gp. S1471491423000758$$n8$$p646-658$$tTrends in molecular medicine$$v29$$x1471-4914$$y2023
000276063 909CO $$ooai:inrepo02.dkfz.de:276063$$pVDB
000276063 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8267c7c8b2e91db98a49f832eb5b99bb$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000276063 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)27fb0d2bd2832c8c977e636025736942$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000276063 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1eee9e84c0f8c90a97fe40b6e8252a23$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000276063 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0116f5652cc0dbf455e3aa3914740230$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000276063 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9d57fe3333789705a9ceb9ca904e83e$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000276063 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000276063 9141_ $$y2023
000276063 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
000276063 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
000276063 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRENDS MOL MED : 2022$$d2023-10-25
000276063 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000276063 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000276063 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000276063 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000276063 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000276063 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000276063 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000276063 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-25
000276063 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2023-10-25
000276063 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000276063 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bTRENDS MOL MED : 2022$$d2023-10-25
000276063 9202_ $$0I:(DE-He78)A430-20160331$$kA430$$lNWG-KKE Translationale Chirurgische Onkologie$$x0
000276063 9201_ $$0I:(DE-He78)A430-20160331$$kA430$$lNWG-KKE Translationale Chirurgische Onkologie$$x0
000276063 9201_ $$0I:(DE-He78)A420-20160331$$kA420$$lPersonalisierte Medizinische Onkologie$$x1
000276063 9200_ $$0I:(DE-He78)A430-20160331$$kA430$$lNWG-KKE Translationale Chirurgische Onkologie$$x0
000276063 980__ $$ajournal
000276063 980__ $$aVDB
000276063 980__ $$aI:(DE-He78)A430-20160331
000276063 980__ $$aI:(DE-He78)A420-20160331
000276063 980__ $$aUNRESTRICTED